Job opening in Zydus Cadila

We are looking for candidates with experience in Viral and/or bacterial testing (Department – QC Vaccine)

#qc #qcjobs #producttesting #analysis #vaccines #vaccineQC


Qualification: M.Sc. .Microbiology/Biology/Biotechnology

Years of Experience: 5 to 10 years

Role : Analyst (Individual Contributor)

Job Description:

1. Preparation of plan for day to day testing activities of in-process, drug substance and drug product samples (Viral Vaccine like Infuenza, MMR, varicella, Hepatitis, DNA vaccines) as per approved procedure and specification.
2. Having exposure/knowledge of different test parameter like; HA Content, Ovalbumin content, Total protein content, Mycoplasma testing, cell culture analysis, Virus titre, DNA Content etc.
3. Planning and execution for the analysis of “Bacterial Vaccine” like Typhoid, TCV, Diphtheria, Tetanus, pertussis etc. as per approved procedure and specification.
4. Having exposure/knowledge of handling of QC Equipment like UFLC, Architecture, Elisa, Ion Chromatography, gas chromatography, Spectrophotometer, FTIR etc.
5. Routine calibration/ verification of Virology lab. Instrument/equipment as per schedule.
6. Preparation and maintenance of Reference Standard, working standard.
7. Review of analytical records.
8. Initiation of change control or deviation/OOS (if any).
9. Maintenance of log books. Self-training and imparting to concern personnel.
10. Should have analytical approach and having experience for trend analysis, data evaluation & statistical calculations.
21. Online monitoring and Maintaining and records of daily monitoring logs, usage logs of instrument/equipment etc.

Interested candidates may share their CV at

Job opening in BIGTEC LABS

We are Hiring !!

EXPERIENCE: Minimum 2years
1. Execute oligonucleotide synthesis and purification protocols
2. Operate and maintain oligonucleotide synthesis instruments and other scientific equipment
3. Record all experiments carried out, all analytical data collected and

1. Must have hands-on experience in oligonucleotide synthesis and
2. Should have a good understanding of synthetic organic chemistry synthesis
3. Must have experience in HPLC technique
4. Good understanding of safety and correct laboratory practices

Note: Please share one page resume only. Any other resume bigger than one page will not be considered.

Bone Marrow: The Start of All

Red and yellow, spongy matter,
Squeezed inside the sternum, thigh bones and hip bones,
Sometimes stored, 
To be used later,
For someone of your own.

Red part - a blood making factory,
Stem cells rising to make RBCs, WBCs and Platelets,
Many factors involved, 
Like bees surrounding a nectary,
Working tirelessly, never ever resting.

Yellow part – a supporting stromal partner,
Concoction of adipocytes, chondrocytes, osteocytes,
Serving the microenvironment with great honor,
Working together just right.

Oh! many times ill-luck strikes,
Depleting blood cells from the sites,
Life threatening - aplastic anemia,
Or any leukemia.

But, there’s nothing to worry,
Bone marrow transplant is the answer,
Matching it right with the patient,
To do away with the blood cancer,
A new hope awaits………………………….
Photo created using Biorender

Written by Dr. Vandana Sharma

About poet:

Vandana Sharma is a researcher and earned her PhD degree under the guidance of Professor Tulika Seth, from All India Institute of Medical Science, New Delhi. Poetry writing is her hobby. Her poems have appeared in various poetry journals and magazines like Harvests of New Millennium, Sky Island Journal, Rewrite Sunlight Anthology, The Ashvamegh International Journal & Literary magazine, VerbalArt. Her poems can be read at:

Job opening in Amity Institute of Biotechnology

The Amity Institute of Biotechnology, Amity Mumbai is looking for Outstanding Food Technology Researchers (with Ph.D. degrees in Food Technology/Food Science/Food Processing) for the faculty position. Teaching or PostDoc or research experience is must. Ph.D freshers can apply for Visiting position. Candidates from CFTRI/IIFPT/NIFTEM/ICT will be preferred.

Send your CV/Resume to

Nano medicine therapeutics for targeted Gene Silencing in Ovarian cancer

Dr. Manu Smriti Singh’s interview with Bio Patrika hosting “Vigyaan Patrika”, a series of author interviews. Dr. Singh completed her Doctorate from University of Bonn. She completed her Post-Doctoral Research from Tel Aviv University and Hebrew University of Jerusalem, Israel in 2020. At present, she is a Faculty at Department of Biotechnology, Bennett University with focus on tumor microenvironment and Cancer Nano medicine. Here, Manu Smriti talks about her work titled “Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer” published in Small journal.

Listen audio

How would you explain your paper’s key results to the non-scientific community?

Nucleic Acids are prone to degradation when administered in vivo. Also, negative charge makes the delivery into cells challenging due to the barrier posed by the anionic cell membrane. Covid19 vaccines manufactured by Moderna and Pfizer/ BioNTech are based on messenger RNA (mRNA) – a transient genetic material that carries information from DNA (in nucleus) to form protein (in cytoplasm). In my work, we have used the same delivery vehicle as Moderna’s vaccine but to deliver small interfering RNA (siRNA) instead of mRNA. The common RNA delivery vehicle we have used are termed Lipid Nanoparticles (LNPs).

Clinically, chemotherapy is the conventional treatment for cancer but is accompanied by unwanted toxicity to healthy tissues. Gene therapy is increasingly gaining clearance from FDA following successful clinical trials and would become more mainstream in cancer treatment as well. For example- Tisagenlecleucel and Patisiran for the treatment of B-cell Acute Lymphoblastic Leukemia and Transthyretin-mediated amyloidosis respectively. Here, we used siRNA as the therapeutic modality which works on the principle of RNA interference for which Craig Mello and Andrew Fire shared the Nobel Prize just 15 years ago (2006). Delivery of siRNA to cancer cells can lead to downregulation of target genes and reduce the production of desired protein, crucial for proliferation of cancer cell.

For this work we chose two targets- eIF3c and PLK1. eIF3c (Eukaryotic Initiation Factor Subunit 3c) which plays a role in starting protein translation process and drives tumorigenesis. PLK1 (Polo Like Kinase 1) plays a role in malignant transformation by triggering cell division. LNPs encapsulating siRNA against PLK1 (TKM-080301) has shown promising leads so far and has already cleared Phase I/II trial for hepatocellular carcinoma. The siRNA against both targets- (si-eIF3c and si-PLK1) were co-encapsulated in LNPs facilitated by a microfluidic mixing device. These LNPs were further coated with Hyaluronan (HA) which specially binds to cell surface receptor called CD44.

CD44 is highly expressed in ovarian cancer cells (also observed in patient’s ovary tumor and ascites samples). The HA-coating was to enable active targeting of cancer cells by LNPs (tNP) as opposed to uncoated LNPs (uNP). Our LNP were ~60nm in size.

Key results:

  • We confirmed the functional activity of both siRNA’s individually on cancer cells growing in 2D and 3D cell culture. si-eIF3c-LNP inhibited global protein synthesis and si-PLK1-LNP arrested cells at G2/M-phase of cell cycle; both the process leading to death of cancer cells.
  • The above results were due to robust gene silencing of both genes in vitro and in vivo (in mice cancer tissues)
  • Another important observation was the selective and enhanced targeting to CD44 expressing cells in mice tumor tissue with tNP (in comparison to uNP)
  • After 4 injections, we found a durable response in mice in the combination treatment group which improved the median survival and overall survival. 60% mice survived in combination treatment as compared to none of the mice surviving in the control group or with empty nanoparticles (only carrier).

What are the possible consequences of these findings for your research area?

Clinically, ovarian cancer is diagnosed in advanced stages (III/IV) at which the patient’s 5-year survival is only 30%. Most studies on ovarian cancer start an early treatment on day 5 onwards when the tumor is not even established in vivo. We deliberately injected mice with siRNA-encapsulated-LNPs on day 15 onwards to mimic clinical settings of late stage patients. In the combination siRNA treatment group, we observed 60% survival at a low dose of 1mg/kg mice body weight.

The fact that the two siRNA’s we encapsulated, can be replaced with other siRNA targets for a more personalized approach for an individual’s treatment makes LNPs a promising candidate in future therapies. This implies that depending on the signature profile of the patient – chemotherapy resistant/ recurring/ unique mutation leading to altered metabolism/ quiescent gene in the hypoxic core etc. can be identified, and tailor-made LNPs encapsulating siRNA1 + siRNA2 or more can be formulated and administered to the patient.

Gene therapy is highly specific in terms of targeting specific genes, which are up regulated in cancer, thereby reducing chances of undue toxicity to healthy tissue. In addition, HA-coating can provide cancer-tissue specific delivery as we observed in our mice studies.

What was the exciting moment (eureka moment) during your research?

While we knew that there is a robust gene silencing and in vitro anti-tumor activity, I was not sure if the gene therapy will be strong enough for an advanced stage metastasized tumor. Almost 80% of the ovarian cancer patients come to the gynaecologist in advanced stages with swollen abdomen filled with a fluid called ascites. The fluid comprises of tumor-cell clusters which shedfrom the growing tumor in the ovary. So, we were assuming to observe silencing of the target genes in ascites of the mice because it was closer to the site of injection (intraperitoneal). But the most exciting part was to observe a robust and reproducible silencing in the key tissues associated with ovarian cancer pathophysiology- ovary, omentum and distant from site of injection. This was a direct evidence of functional activity of siRNA activity in vivo.

What do you hope to do next?

In a prior work, I developed an in vivo tumor model based on 3D spheroids (ovarian cancer) and observed the role of tumor microenvironment in delivery of chemotherapy, biological therapy and nanomedicine. As I set up my lab, my focus will be in understanding non-cancer supportive cells of the tumor microenvironment specifically carcinoma-associated fibroblasts and endothelial cells along with developing nanomedicine to target them besides cancer cells.

Another area I am interested in exploring is early cancer diagnosis, which I think should be given more attention than cancer therapeutics as we move ahead.

Where do you seek scientific inspiration?

As much as I would like to give a philosophical answer to that, the reality is – review of literature. I try to do a thorough reading before starting a project and also as it continues. I believe that the scientists are a very curious lot and most of the ideas that come to the mind have already been worked upon. I try to look for the questions that have remained unanswered and try to work on those gaps to find solutions.

Of course, both my Post-doctoral mentors Prof. Dan Peer (Tel Aviv University) and Professor Emeritus Yechezkel Barenholz (Hebrew University of Jerusalem) have been and will continue to be a constant source of inspiration.

How do you intend to help Indian science improve?

My research experience at Israeli Universities has exposed me to the entrepreneurship-driven academic learning. In India, the greatest asset is talented students and researchers. On one hand, I aim to focus on predominantly cancer-related diagnostic and therapeutic research, while on the other hand to translate potential projects into commercial products. In this direction, I am teaching Intellectual Property Right (IPR) at Bennett University to the students to understand IP issues related to research products commercialization.

I would also like to work at the interface of Industry and Hospitals because I believe that academicians cannot work in isolation and must try to understand the problems at hand (in Indian context here). Academia-Industry-Hospital collaborations can address problems in a more concerted and timely manner in terms of translational output.


Singh, M. S., Ramishetti, S., Landesman-Milo, D., Goldsmith, M., Chatterjee, S., Palakuri, R., Peer, D., Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer. Small 2021, 17, 2100287.


Edited by: Pratibha Siwach

miRNA compartmentalisation paves a new avenue in neuroinflammatory process of Alzheimer’s Disease

Mr. Dipayan De’s interview with Bio Patrika hosting “Vigyaan Patrika”, a series of author interviews. Dipayan is from CSIR-Indian Institute of Chemical Biology, Kolkata. He started his Science journey from St. Xavier’s College, Kolkata where he undertook a bachelor’s degree in Science majoring in Microbiology and went onto do a Master’s in Biochemistry at University of Calcutta. Currently, he is pursuing his Ph.D. under the supervision of Dr. Suvendra Bhattacharyya at CSIR-Indian Institute of Chemical Biology, Kolkata. From the very beginning, his specific scientific interest in the field of small RNA was nurtured by his mentor Dr. Bhattacharyya. Under the eminent guidance of Dr. Bhattacharyya, he delved into exploring the details of how cellular organelles regulate small RNA activity in mammalian cells. One of his recent findings highlights how mTOR reactivation improves memory and disease pathology by regulating miR-146a activity in Alzheimer’s disease brain that has been published in Molecular Therapy: Nucleic Acids (De et al., 2021). He fosters a deep passion in the imaging field and would like to dig deep into the fascinating realms of microscopy in the future. When not in the laboratory, Dipayan is an ardent foodie and loves to travel. Here in this interview, Dipayan discusses his new findings “Amyloid-β oligomers block lysosomal targeting of miRNPs to prevent miRNP recycling and target repression in glial cells ” published in “Journal of Cell Science”.

Listen audio

How would you explain your paper’s key results to the non-scientific community?

Major challenges for Alzheimer’s disease (AD) patients include forgetfulness and decline in motor activities. The pathological hallmark of Alzheimer’s disease these patients include Amyloid β plaque formation in the brain, resulting in neurodegeneration and loss of neurons in the central nervous system. One of the major reasons for neurodegeneration is the occurrence of uncontrolled inflammation within the brain. There are star-shaped glial cells known as astrocytes present around the neurons which regulate this inflammatory process via the expression of cytokines. Within these glial cells, tiny RNA molecules known as miRNA are present which can repress the expression of cytokine mRNA and thus regulating the inflammation process. However, with the exposure of amyloid-β plaques there is an increase in the expression of miRNA and cytokine mRNA within glial cells. In this study, we asked that in spite of the increase in miRNAs expression within astrocytes, why the cytokine production fails to decline in order to subside the inflammation process. Interestingly, we found that, although present in abundance, the miRNA activity is diminished within glial cells when exposed to amyloid-β plaques. Furthermore, miRNA fails to bind to their target cytokine mRNA because of differential localization inside the cell. β-amyloid treated glial cells show a faulty endosome maturation pathway which leads to compartmentalization of miRNA and their target mRNA into two separate cellular compartments. We found miRNA along with the Ago2 protein present inside the early endosome but cytokine mRNAs to be associated with the endoplasmic reticulum-associated polysomes. Such segregation of miRNA from their cytokine mRNA results in target de-repression thus triggering an uncontrolled inflammation in the diseased neurons. This phenomenon subsequently leads to the demise of the neuronal cells.

Figure 1. Aβ disrupts miRNP recycling to increase cytokine production in glial cells

One of the most interesting findings from our study is how endosome maturation can regulate miRNA activity.

What are the possible consequences of these findings for your research area?

One of the most interesting findings from our study is how endosome maturation can regulate miRNA activity. Our findings in Alzheimer’s disease system showed how a cell biological process like vesicular trafficking has the potential to fine tune the gene expression process within the cell. Similar phenomenon can be speculated for other neurodegenerative disease which need to be investigated further. Another interesting aspect is that miRNA with RNA binding proteins phase separated to form specialized RNA aggregates known as processing Bodies or P Bodies. Presence of RNA aggregates can be found in many neuronal and non-neuronal diseases. These phase separated bodies not only act as storage sites of RNA and RNA binding proteins but also create a micro environment for other cellular functions such as different forms of cell signalling. Furthermore, we also found that depletion of P-Bodies relieves the AD associated inflammation process in glial cells which indicates that RNA granules can play an important role in the progression of these neurodegenerative diseases or any other diseases that associate with increased inflammation.

Figure 2. Phase separated RNA granules in yellow (P-body) can be seen throughout the cytoplasm where endocytic pathway has been disrupted

What was the exciting moment (eureka moment) during your research?

Functional assays showed lower miRNA activity in the amyloid exposed glial cells. Interestingly, all the three major component of the repression system i.e. miRNA, major repression protein Ago2 and target mRNA were found to be abundant in the cell. Moreover, the association between Ago2 and miRNA that forms the functional miRNPs was also found to be intact. For a long time we were struggling to figure out why in spite of all the machinery of the repression system being in order, there was a drop in miRNA activity? The first break that we got was when we fractionated the cell and tried to find out localization of all the three components. Cell fractionation assay first showed us although all the three components are present, yet they are localized in the different compartments of the cell. The fact that cellular compartmentalization can cause a problem in the miRNA activity was pretty exciting. We went on and found endo-lysosomal fusion has a role on target mRNA recognition, which is pretty novel.

What do you hope to do next?

Currently, I am on the verge of submitting my thesis for the completion of my Ph.D. Also, I am looking for a post-doctoral position that will help me expand my microscopy and biochemistry knowledge especially in the field of molecular cell biology. In the long run, I see myself running a laboratory to explore some of my ideas in the field of cell biology. 

Where do you seek scientific inspiration?

I have been very privileged through out my Ph.D. to be surrounded by dynamic and visionary people in the field of science. I believe that multifaceted factors have shaped CSIR-IICB to become a great place to do science. My supervisor Dr. Suvendra Bhattacharyya had a big impact on my Ph.D. career both on and off the laboratory. His teachings imparted me the ability to think critically while proceeding with the scientific problem and the propensity to ask relevant questions regarding the research problems. Additionally, I had fantastic lab mates and lab seniors who have been really fun to work with. Last but not least my wife, Subhalakshmi Guha, a Ph.D. student in the field of neuroscience has been a huge support and motivation for me throughout.

How do you intend to help Indian science improve?

If we look at the sheer number of talented scientists, doctors, and engineers in different fields in this country and their intelligence, India possesses huge potential for scientific greatness. Nowadays science has become multi-disciplinary and to answer a scientific question all the different fields of science need to merge together. A good collaborative environment between the different fields of science can help us immensely. Also, we need to find the right balance between basic and translational research so that the findings of the desk can be implemented in the right manner to improve human life.


Dipayan De, Suvendra N. Bhattacharyya; Amyloid Beta oligomers prevents Lysosomal targeting of miRNP to stop its recycling and target repression in glial cells. J Cell Sci 2021; jcs.258360. doi:

Lab website:

Edited by: Sukanya Madhwal

GlmU: One Step Closer towards Breaking the Great Wall of Tuberculosis

Dr. Meetu Agarwal and Dr. Vijay Soni’s joint interview with Bio Patrika hosting “Vigyan Patrika”, a series of author interviews. Meetu and Vijay are joint-first authors on the recent research paper “Unique C-terminal extension and interactome of Mycobacterium tuberculosis GlmU impacts its in vivo function and the survival of the pathogen”, published in Biochem J (2021). In this interview, they talk about this work and its relevance in the context of the tuberculosis.

Meetu Agarwal, Ph.D., is currently working as an assistant professor at the department of molecular medicine, Jamia Hamdard University. Dr. Meeetu Agarwal did her Postdoctoral research at the National Institute of Immunology, New Delhi. Dr. Meetu has completed her Ph.D. from Jawaharlal Nehru University (JNU), New Delhi.

Vijay Soni, Ph.D., is currently working as an instructor of microbiology in medicine at Weill Cornell Medical College, New York. Using a microbial metabolomics approach, he is studying drug metabolism in the context of drug-resistant Mycobacterium tuberculosis. Dr. Soni has completed his Ph.D. from BITS-Pilani Hyderabad and the National Institute of Immunology (NII, Delhi).

Listen audio

How would you explain your key results to the non-scientific community?

It is always the notion that to be simple is good rather than to being complex. However, the vast spectrum of living organisms ranges from single cellular bacterium to multicellular plants and animals. They all have their unique ways of survival and that growth. These different types of organisms can also interact with each other and hold a mutual relationship. For example, our gut flora consists of many bacteria, archaea, and fungi. In such cases, participants either exploit or share the nutrition and niche for better survival and growth. Most of the microbes in the human body are helpful in various biological functions such as digestion, educating our immune system, toxin neutralization, etc. While some of them are not. They can enter our body and cause severe harm, also known as infection. 

The human body has both natural and acquired ways to fight against these harmful microorganisms. But still, due to advanced evolutionary capabilities, sometimes they escape from it and successfully establish the infection. Interestingly, some can stay hidden or inactive for a long time and invade our system when our immune stamina is low. Mycobacterium tuberculosis (Mtb) is one of the smart bacteria which causes the commonly known disease TB (tuberculosis).

According to sources, a quarter of the world’s population (1.7 billion people) carries this microorganism (latently), and almost 159 people die every hour. Therefore, it is vital to understand the biology of the bacteria causing TB. Doctors are using various kinds of combinational drug regimens, and scientists are developing new sets of antibiotics and vaccines to combat it. 

One small step towards it, in the current research article, we have characterized few important and unique features of an essential gene of TB causing bacteria, named glmU. Just like our skin, microorganisms are also surrounded by a protective layer, known as “cell wall”. And this gene (glmU), present in most of the bacteria, including Mtb, is one of the key members to produce the cell wall. Our study deciphers that glmU in Mtb holds some distinct vital features that can be targeted while designing and developing new drugs against TB.


our research provides a way to design new sets of inhibitors against these particular topographies of glmU, which can then indirectly affect many more pathways (glmU interacting partners). 

What are the possible consequences of these findings for your research area?

Although humans and bacteria are genetically diverse, the fundamental biochemical processes hold great levels of similarities. Therefore, it is difficult to select a biological molecule or process that can unambiguously affect the survival of an infection-causing bacteria (not the beneficial bacteria). glmU is present in many bacteria, but with the help of molecular biology and genetic engineering, our research shows that this gene (glmU) has distinct structural features and interactions with other important proteins, exclusive to Mtb glmU. It’s like one bullet, multiple targets. Thus, our research provides a way to design new sets of inhibitors against these particular topographies of glmU, which can then indirectly affect many more pathways (glmU interacting partners). 

What was the exciting moment (eureka moment) during your research?

We believe that every result, positive or negative, is a eureka moment for a researcher because it helps us strengthen or modify our hypothesis. Literature is full of many such studies talking about numerous characteristic characters of GlmU from various microorganisms. As GlmU is a very conserved protein and we were expecting that complementation of this gene in a glmU (gene) knockout strain of Mtb, would help Mtb survive. But we were wrong. We tried various closely related genes, and none of them rescued the bacteria, even GlmU from Mycobacterium smegmatis, which is the same family strain (with significant similarities). It was our awe moment and motivated us to dive deep into it. 

What do you hope to do next?

We as a researcher always hope to better the things we are already doing and continue working towards that. We have explored various dimensions of GlmU such as biology, role in infection, and crystal structure. GlmU synthesizes the fundamental building blocks of the bacterial cell wall, and with our in-depth understanding, we would like to explore other unknown biological and biochemical functions of GlmU and harness them for the development of better inhibitors against TB. 

Where do you seek scientific inspiration?

MA: I think that scientific inspiration comes in different forms to a scientist or a researcher. Primarily, its self-interest when you entered into the field. Since now you are exposed to the real world of research it can come from your mentors, colleagues, and most importantly from ongoing research into the field. That brings the importance of scientific meetings and conferences into the picture.

VS: My scientific inspiration comes from nature, observations, and questions. Every time I see any phenomenon or problem, my mind seeks the reason or solutions for it, and that drives me to read literature, discuss with mentors and colleagues and finally design experiments to test it. The quest for the unknown clicks in the brain and fuels my imagination to connect the dots to make a better picture. 

How do you intend to help Indian science improve?

Indian science has a huge potential and provides us with several opportunities. We intend to provide a very enthusiastic and learning environment in our research group and never let down anyone’s scientific temperament. We also believe in collaborative learning; therefore, we try to connect with new budding research minds and provide the necessary training in our laboratories. 


Meetu Agarwal, Vijay Soni, Suresh Kumar, Biplab Singha, Vinay Kumar Nandicoori; Unique C-terminal extension and interactome of Mycobacterium tuberculosis GlmU impacts its in vivo function and the survival of the pathogen. Biochem J 2021; BCJ20210170. doi:

Edited by: Nivedita Kamath

Job opening in Biogenuix Medsystems

Asst. Product Manager Position at Biogenuix Medsystems Pvt. Ltd.
Designation: Assistant Product Manager (Cell Culture, Immunology, Molecular Biology Range of Biogenuix)
Role & Responsibility:
Responsible for product life cycle of the assigned portfolio.
Responsible for developing communication plan, positioning strategy, market segmentation, product differentiation, promotional plan/promotional campaigns for the assigned portfolio.
Mapping & tracking of competition in terms of product, communication, promotion, segmentation, pricing.
Screening of web leads & giving inputs to support team for respective portfolio.
Monitoring of CRM, Customer database management for the respective product portfolio.
Technical Training : Offline & online (Webinar) for sales/support team for respective product portfolio.
Co-ordination with principal/supplier for new launches, technical trainings, product complaint management, promotional campaigns.
Follow-up/Tracking of promotional plan for product portfolio from principal.
e-Marketing: Development of tools & resources for e-Marketing for assigned product portfolio to be published.
Website management/updation for respective portfolio.
Demos/Technical Presentations to customers.
Active communication & close monitoring with sales & support team to ensure proper implementation of the strategy.
Periodic visits to customers (8-10 day/Month) along with sales team to get insight about actual customer feedback & to provide on job training to sales/support team for the assigned product portfolio.
Screening/Monitoring of daily Reports of sales team with a perspective of individual portfolio and giving inputs/feedbacks to the team.
Location: New Delhi.
Qualification: Minimum MTech/MSc in Biotechnology or higher (Phds) with good academic background, good communication skills & passion for travel & meeting people.
Kindly share CV to